AMNEAL PHARMACEUTICALS ($AMRX) is expected to release its quarterly earnings data on Friday, May 2nd before market open, per Finnhub. Analysts are expecting revenue of $729,796,403 and earnings of $0.15 per share.
You can see Quiver Quantitative's $AMRX stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
AMNEAL PHARMACEUTICALS Insider Trading Activity
AMNEAL PHARMACEUTICALS insiders have traded $AMRX stock on the open market 16 times in the past 6 months. Of those trades, 0 have been purchases and 16 have been sales.
Here’s a breakdown of recent trading of $AMRX stock by insiders over the last 6 months:
- TUSHAR BHIKHUBHAI PATEL sold 5,000,000 shares for an estimated $41,750,000
- GAUTAM PATEL has made 0 purchases and 5 sales selling 320,000 shares for an estimated $2,668,000.
- JASON B. DALY (EVP, Chief Legal Officer) has made 0 purchases and 4 sales selling 147,322 shares for an estimated $1,282,832.
- ANDREW S BOYER (Executive Vice President) sold 125,000 shares for an estimated $1,111,250
- TASOS KONIDARIS (Executive Vice President & CFO) sold 100,000 shares for an estimated $891,000
- EMILY PETERSON ALVA sold 80,000 shares for an estimated $712,000
- DEBORAH M. AUTOR has made 0 purchases and 2 sales selling 40,000 shares for an estimated $334,073.
- JOHN KIELY sold 17,058 shares for an estimated $142,946
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
AMNEAL PHARMACEUTICALS Hedge Fund Activity
We have seen 118 institutional investors add shares of AMNEAL PHARMACEUTICALS stock to their portfolio, and 66 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS GROUP AG removed 20,107,524 shares (-92.4%) from their portfolio in Q4 2024, for an estimated $159,251,590
- FOSUN INTERNATIONAL LTD removed 1,720,855 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $13,629,171
- WOODLINE PARTNERS LP removed 1,037,471 shares (-64.7%) from their portfolio in Q4 2024, for an estimated $8,216,770
- NANTAHALA CAPITAL MANAGEMENT, LLC added 995,586 shares (+37.3%) to their portfolio in Q4 2024, for an estimated $7,885,041
- PHOCAS FINANCIAL CORP. removed 813,301 shares (-80.1%) from their portfolio in Q4 2024, for an estimated $6,441,343
- ACADIAN ASSET MANAGEMENT LLC added 546,736 shares (+46.7%) to their portfolio in Q4 2024, for an estimated $4,330,149
- ARROWSTREET CAPITAL, LIMITED PARTNERSHIP removed 527,921 shares (-25.5%) from their portfolio in Q4 2024, for an estimated $4,181,134
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
AMNEAL PHARMACEUTICALS Government Contracts
We have seen $173,571 of award payments to $AMRX over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- XYREM (SODIUM OXYBATE) ORAL SOLUTION.: $173,571
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
AMNEAL PHARMACEUTICALS Analyst Ratings
Wall Street analysts have issued reports on $AMRX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Piper Sandler issued a "Overweight" rating on 11/11/2024
To track analyst ratings and price targets for AMNEAL PHARMACEUTICALS, check out Quiver Quantitative's $AMRX forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
